Press release
Hereditary Transthyretin Amyloidosis Pipeline Drugs Report 2025: MOA, Emerging Therapies, Clinical Trials, Treatment | DelveInsight
Curious about the latest updates in the Hereditary Transthyretin Amyloidosis Pipeline? Click here to explore the therapies and trials making headlines @ Hereditary Transthyretin Amyloidosis Pipeline Outlook Report [https://www.delveinsight.com/sample-request/hereditary-transthyretin-amyloidosis-hattr-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Key Takeaways from the Hereditary Transthyretin Amyloidosis Pipeline Report
* On 15 October 2025, Intellia Therapeutics announced a study will be conducted to evaluate the efficacy and safety of a single dose of nexiguran ziclumeran (NTLA-2001) compared to placebo in participants with ATTRv-PN.
* On 14 October 2025, Eidos Therapeutics, a BridgeBio company conducted a study is to evaluate the long-term safety and tolerability of acoramidis in patients with an established diagnosis of ATTR-CM and heart failure who are concomitantly treated with currently recommended heart failure therapies. Secondary efficacy and PD objectives will be assessed. Exploratory objectives may also be assessed.
* DelveInsight's Hereditary Transthyretin Amyloidosis Pipeline report depicts a robust space with 8+ active players working to develop 8+ pipeline therapies for Hereditary Transthyretin Amyloidosis treatment.
* The leading Hereditary Transthyretin Amyloidosis Companies such as Alnylam Pharmaceuticals, Ionis Pharmaceuticals, Eidos Therapeutics, Intellia Therapeutics, Corino Therapeutics, Novo Nordisk and others.
* Promising Hereditary Transthyretin Amyloidosis Therapies such as Patisiran, Vutrisiran, Inotersen, Eplontersen, Tafamidis Meglumine, NTLA-2001, Revusiran (ALN-TTRSC) and others.
Want to know which companies are leading innovation in Hereditary Transthyretin Amyloidosis? Dive into the full pipeline insights @ Hereditary Transthyretin Amyloidosis Clinical Trials Assessment [https://www.delveinsight.com/sample-request/hereditary-transthyretin-amyloidosis-hattr-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
The Hereditary Transthyretin Amyloidosis Pipeline Report provides disease overview, pipeline scenario and therapeutic assessment of the key pipeline therapies in this domain. The Hereditary Transthyretin Amyloidosis Pipeline Report also highlights the unmet needs with respect to the Hereditary Transthyretin Amyloidosis.
Hereditary Transthyretin Amyloidosis Overview
Hereditary transthyretin (ATTR) amyloidosis is characterized by a slowly progressive peripheral sensorimotor and/or autonomic neuropathy as well as non-neuropathic changes of cardiomyopathy, nephropathy, vitreous opacities, and CNS amyloidosis. It is a rare inherited condition characterized by abnormal build-up of a protein called amyloid in the body's organs and tissues.
Hereditary Transthyretin Amyloidosis Emerging Drugs Profile
* Vutrisiran: Alnylam Pharmaceuticals
Vutrisiran is an investigational, subcutaneously administered RNAi therapeutic in development for the treatment of ATTR amyloidosis, which encompasses both hereditary (hATTR) and wild-type (wtATTR) amyloidosis. It is designed to target and silence specific messenger RNA, blocking the production of wild-type and variant transthyretin (TTR) protein before it is made. Quarterly administration of vutrisiran may help to reduce deposition and facilitate the clearance of TTR amyloid deposits in tissues and potentially restore function to these tissues. Vutrisiran utilizes Alnylam's Enhanced Stabilization Chemistry (ESC)-GalNAc-conjugate delivery platform, designed for increased potency and high metabolic stability that allows for infrequent subcutaneous injections. HELIOS-B is a randomized, double-blind, placebo-controlled Phase 3 study of ~600 adult patients with ATTR amyloidosis with cardiomyopathy (including both hATTR and wtATTR amyloidosis). The U.S. Food and Drug Administration (FDA) has accepted the Company's New Drug Application (NDA) for vutrisiran, an investigational RNAi therapeutic for the treatment of the polyneuropathy of hereditary transthyretin-mediated (hATTR) amyloidosis in adults. The FDA has set an action date of April 14, 2022 under the Prescription Drug User Fee Act (PDUFA), and the Agency has indicated that they are not currently planning an advisory committee meeting as part of the NDA review.
* AKCEA-TTR-LRx: Ionis Pharmaceuticals
AKCEA-TTR-LRx is an antisense drug developed using Ionis' proprietary LIgand Conjugated Antisense (LICA) technology platform and is designed to inhibit production of TTR. It was discovered by Ionis and is being co-developed by Ionis and Akcea. In a Phase 1 clinical trial, patients treated with AKCEA-TTR-LRx experienced reductions in TTR of up to 94 percent at the highest dose. CARDIO-TTRansform is a global, double-blind, randomized, placebo-controlled Phase III cardiovascular outcome study. It is designed to compare AKCEA-TTR-LRx to placebo in patients with both wild type and hereditary ATTR cardiomyopathy who are on the current available standard of care.
If you're tracking ongoing Hereditary Transthyretin Amyloidosis Clinical trials, this press release is a must-read. Tap to see the breakthroughs @ Hereditary Transthyretin Amyloidosis Treatment Drugs [https://www.delveinsight.com/sample-request/hereditary-transthyretin-amyloidosis-hattr-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
The Hereditary Transthyretin Amyloidosis Pipeline report provides insights into:-
* The report provides detailed insights about companies that are developing therapies for the treatment of Hereditary Transthyretin Amyloidosis with aggregate therapies developed by each company for the same.
* It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Hereditary Transthyretin Amyloidosis Treatment.
* Hereditary Transthyretin Amyloidosis Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
* Hereditary Transthyretin Amyloidosis Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
* Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Hereditary Transthyretin Amyloidosis market.
Hereditary Transthyretin Amyloidosis Companies
Alnylam Pharmaceuticals, Ionis Pharmaceuticals, Eidos Therapeutics, Intellia Therapeutics, Corino Therapeutics, Novo Nordisk and others.
Hereditary Transthyretin Amyloidosis Pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as,
* Oral
* Parenteral
* Intravenous
* Subcutaneous
* Topical
* Molecule Type
Hereditary Transthyretin Amyloidosis Products have been categorized under various Molecule types such as,
* Monoclonal Antibody
* Peptides
* Polymer
* Small molecule
* Gene therapy
* Product Type
From emerging drug candidates to competitive intelligence, the Hereditary Transthyretin Amyloidosis Pipeline Report covers it all - check it out now @ Hereditary Transthyretin Amyloidosis Market Drivers and Barriers, and Future Perspectives [https://www.delveinsight.com/sample-request/hereditary-transthyretin-amyloidosis-hattr-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Scope of the Hereditary Transthyretin Amyloidosis Pipeline Report
* Coverage- Global
* Hereditary Transthyretin Amyloidosis Companies- Alnylam Pharmaceuticals, Ionis Pharmaceuticals, Eidos Therapeutics, Intellia Therapeutics, Corino Therapeutics, Novo Nordisk and others.
* Hereditary Transthyretin Amyloidosis Therapies- Patisiran, Vutrisiran, Inotersen, Eplontersen, Tafamidis Meglumine, NTLA-2001, Revusiran (ALN-TTRSC) and others.
* Hereditary Transthyretin Amyloidosis Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
* Hereditary Transthyretin Amyloidosis Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
Stay ahead in Healthcare Research - discover what's next for the Hereditary Transthyretin Amyloidosis Treatment landscape in this detailed analysis @ Hereditary Transthyretin Amyloidosis Emerging Drugs and Major Players [https://www.delveinsight.com/sample-request/hereditary-transthyretin-amyloidosis-hattr-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Table of Contents
* Introduction
* Executive Summary
* Hereditary Transthyretin Amyloidosis (hATTR): Overview
* Pipeline Therapeutics
* Late Stage Products (Pregistration)
* Vutrisiran: Alnylam Pharmaceuticals
* Drug profiles in the detailed report.....
* Mid Stage Products (Phase II)
* Drug Name: Company Name
* Drug profiles in the detailed report.....
* Early stage products (Phase I)
* PRX 004: Prothena
* Drug profiles in the detailed report.....
* Inactive Products
* Hereditary Transthyretin Amyloidosis (hATTR) Key Companies
* Hereditary Transthyretin Amyloidosis (hATTR) Key Products
* Hereditary Transthyretin Amyloidosis (hATTR)- Unmet Needs
* Hereditary Transthyretin Amyloidosis (hATTR)- Market Drivers and Barriers
* Hereditary Transthyretin Amyloidosis (hATTR)- Future Perspectives and Conclusion
* Hereditary Transthyretin Amyloidosis (hATTR) Analyst Views
* Hereditary Transthyretin Amyloidosis (hATTR) Key Companies
* Appendix
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=hereditary-transthyretin-amyloidosis-pipeline-drugs-report-2025-moa-emerging-therapies-clinical-trials-treatment-delveinsight]
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/hereditary-transthyretin-amyloidosis-hattr-pipeline-insight
Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Hereditary Transthyretin Amyloidosis Pipeline Drugs Report 2025: MOA, Emerging Therapies, Clinical Trials, Treatment | DelveInsight here
News-ID: 4230035 • Views: …
More Releases from ABNewswire
Blue Atlas Marketing Wins Global 100 2026 Award for Best Web Design Company in T …
Blue Atlas Marketing, a leading B2B digital marketing and web development agency, has been honored with the Global 100 2026 Award for Best Web Design Company in Texas. The award recognizes the firm's excellence in design, user experience, and high-performance digital solutions.
Blue Atlas Marketing, a leading B2B digital marketing and web development agency, has been honored with the Global 100 2026 Award for Best Web Design Company in Texas. The…
Fatal Blackout Review 2025: Is This Blackout Survival System Worth the Hype?
Fatal Blackout is a digital survival training program that teaches families how to prepare for and endure long term power outages. It includes guides on energy independence, EMP protection, home defense, food production, and natural medicine. The program is beginner friendly, affordable, and comes with a full one year money back guarantee. Some marketing claims feel dramatic and a few technical parts may challenge total beginners, but the system delivers…
Fence Company in Peekskill, NY - Quality Fence, Inc. Strengthens Local Service O …
Quality Fence, Inc., a trusted fence company in Peekskill, NY, has expanded its wood fence installation services to offer homeowners premium materials and improved installation options. With rising demand across Westchester County, the company now provides enhanced residential fencing solutions designed for better privacy, durability, and long-term property value.
Peekskill, NY - Quality Fence, Inc., a leading fence company in Peekskill, NY [https://qualityfenceny.com/peekskill-ny-fence-contractor/], has expanded its professional service offerings to provide…
The Presidential Family Leverages 5 Million Followers to Launch Luna Luxuria Jew …
The Presidential Family, viral content creators who have amassed over 5 million followers through authentic storytelling across YouTube, TikTok, Instagram, and Facebook, are channeling their influence into Luna Luxuria, a jewelry brand designed to help women feel valued and beautiful every day. The launch demonstrates how digital creators are successfully translating social media success into meaningful product ventures that serve their communities.
The Presidential Family is demonstrating the evolving power of…
More Releases for Hereditary
Unraveling Hereditary Cancer With The Rising Demand For Hereditary Cancer Testin …
Use code ONLINE20 to get 20% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.
What Will the Hereditary Cancer Testing Industry Market Size Be by 2025?
The market encompassing hereditary cancer testing has exhibited robust expansion throughout the recent past, projecting an increase from its value of $4.32 billion in 2024 to reach $4.75 billion for the subsequent year, reflecting a consistent annual…
Leber Hereditary Optic Neuropathy Treatment Market
Introduction
Leber Hereditary Optic Neuropathy (LHON) is a genetic condition that leads to severe vision loss, primarily affecting young adults. This disorder is caused by mutations in mitochondrial DNA, which impairs the function of retinal ganglion cells. As awareness of LHON has grown, so too has the focus on its treatment options. The LHON treatment market is evolving rapidly, driven by advancements in genetic therapies, pharmaceuticals, and supportive care strategies. This…
Hereditary Hemochromatosis Market - Redefining Care, Inspiring Hope: Hereditary …
Newark, New Castle, USA: The "Hereditary Hemochromatosis Market" provides a value chain analysis of revenue for the anticipated period from 2023 to 2031. The report will include a full and comprehensive analysis of the business operations of all market leaders in this industry, as well as their in-depth market research, historical market development, and information about their market competitors.
Hereditary Hemochromatosis Market: https://www.growthplusreports.com/report/hereditary-hemochromatosis-market/8793
This latest report researches the industry structure, sales, revenue,…
Hereditary Angioedema Market Research Report 2032
DelveInsight's "Hereditary Angioedema Market Insights, Epidemiology, and Market Forecast 2032" report delivers an in-depth understanding of the Hereditary Angioedema, historical and forecasted epidemiology as well as the Hereditary Angioedema market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
Hereditary Angioedema (HAE) is a rare genetic disorder caused by the deficiency in functional C1 inhibitor (C1INH) that results in recurrent attacks of localized subcutaneous or…
Hereditary Angioedema - Drug Pipeline Landscape, 2022
Global Hereditary Angioedema Market report from Global Insight Services is the single authoritative source of intelligence on hereditary angioedema market. The report will provide you with analysis of impact of latest market disruptions such as Russia-Ukraine war and Covid-19 on the market. Report provides qualitative analysis of the market using various frameworks such as Porters' and PESTLE analysis. Report includes in-depth segmentation and market size data by categories, product types,…
Hereditary Angioedema - Drug Pipeline Landscape, 2022
Hereditary Angioedema is an infrequent inherited disease that causes substantial swelling in various body tissues, such as the abdomen or face caused by a low level or improper function of a protein called the C1 inhibitor. There are three types of hereditary angioedema namely type I, II, and III.
Hereditary Angioedema is mainly caused by a low level or improper function of a protein called the C1 inhibitor.
Read more about Hereditary…
